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Summary
Background Conﬂ icting evidence exists regarding the association between saturated fatty acids (SFAs) and type 2 diabetes. 
In this longitudinal case-cohort study, we aimed to investigate the prospective associations between objectively measured 
individual plasma phospholipid SFAs and incident type 2 diabetes in EPIC-InterAct participants. 
Methods The EPIC-InterAct case-cohort study includes 12 403 people with incident type 2 diabetes and a representative 
subcohort of 16 154 individuals who were selected from a cohort of 340 234 European participants with 3·99 million 
person-years of follow-up (the EPIC study). Incident type 2 diabetes was ascertained until Dec 31, 2007, by a review of 
several sources of evidence. Gas chromatography was used to measure the distribution of fatty acids in plasma 
phospholipids (mol%); samples from people with type 2 diabetes and subcohort participants were processed in a 
random order by centre, and laboratory staﬀ  were masked to participant characteristics. We estimated country-speciﬁ c 
hazard ratios (HRs) for associations per SD of each SFA with incident type 2 diabetes using Prentice-weighted Cox 
regression, which is weighted for case-cohort sampling, and pooled our ﬁ ndings using random-eﬀ ects meta-analysis. 
Findings SFAs accounted for 46% of total plasma phospholipid fatty acids. In adjusted analyses, diﬀ erent individual 
SFAs were associated with incident type 2 diabetes in opposing directions. Even-chain SFAs that were measured 
(14:0 [myristic acid], 16:0 [palmitic acid], and 18:0 [stearic acid]) were positively associated with incident type 2 diabetes 
(HR [95% CI] per SD diﬀ erence: myristic acid 1·15 [95% CI 1·09–1·22], palmitic acid 1·26 [1·15–1·37], and stearic acid 
1·06 [1·00–1·13]). By contrast, measured odd-chain SFAs (15:0 [pentadecanoic acid] and 17:0 [heptadecanoic acid]) were 
inversely associated with incident type 2 diabetes (HR [95% CI] per 1 SD diﬀ erence: 0·79 [0·73–0·85] for pentadecanoic 
acid and 0·67 [0·63–0·71] for heptadecanoic acid), as were measured longer-chain SFAs (20:0 [arachidic acid], 
22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid]), with HRs ranging from 0·72 to 0·81 (95% CIs 
ranging between 0·61 and 0·92). Our ﬁ ndings were robust to a range of sensitivity analyses.
Interpretation Diﬀ erent individual plasma phospholipid SFAs were associated with incident type 2 diabetes in 
opposite directions, which suggests that SFAs are not homogeneous in their eﬀ ects. Our ﬁ ndings emphasise the 
importance of the recognition of subtypes of these fatty acids. An improved understanding of diﬀ erences in sources 
of individual SFAs from dietary intake versus endogenous metabolism is needed.
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Introduction
Saturated fatty acids (SFAs) are generally thought to have 
detrimental eﬀ ects on health, as represented by the 
widespread public health message advising a reduction 
in SFA intake to less than 10% or even 7% of total energy 
to beneﬁ t cardiometabolic health, including lowering of 
type 2 diabetes risk.1 However, little evidence exists to 
support adverse eﬀ ects of high SFA intake on risk of 
type 2 diabetes.2 Indeed, the Women’s Health Initiative 
Diet Modiﬁ cation Trial3 suggested no beneﬁ t of a 
reduction in SFA intake on the incidence of type 2 
diabetes. Accumulating evidence suggests that intake of 
dairy products, which are typically high in SFA content, 
is inversely associated with type 2 diabetes,4,5 which, 
together with the null or inconsistent evidence about 
total SFA intake and risk of type 2 diabetes, has raised 
doubts about whether all SFA intake has adverse health 
eﬀ ects.
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Previous studies of dietary SFA intake have had 
inconclusive results, limited by measurement error of 
dietary assessment, and have focused on total SFA 
intake without analysis of SFA intake varying by carbon 
chain lengths. The objective measurement of SFAs with 
diﬀ erent carbon chain lengths in blood fractions 
enables assessment of individual SFAs.6 SFAs in blood 
can be directly interpreted as dietary SFAs for fatty 
acids that are good biomarkers of intake, such as 15:0 
(pentadecanoic acid) and 17:0 (heptadecanoic acid), 
which are exogenously derived from dietary dairy fats.6–8 
However, interpretation is more complex for SFAs like 
palmitic acid (16:0) and stearic acid (18:0), which are 
synthesised endogenously through de-novo lipogenesis 
stimulated by increased intake of carbohydrates and 
alcohol,6,9–12 and which might only partly represent 
dietary intake.6,13 The extent to which diﬀ erent dietary 
components can induce de-novo lipogenesis varies.11 
Additionally, uncertainties remain about the extent to 
which dietary SFAs are incorporated into blood SFAs, 
and the relative contri bution of de-novo lipogenesis 
versus habitual diets to the amounts of SFAs circulating 
in the blood.14 However, the varying eﬀ ects of diﬀ erent 
blood SFAs on the risk of type 2 diabetes are of scientiﬁ c 
and public health interest. Only a few small studies 
have assessed a range of circulating SFAs,15–21 and 
evidence supporting asso ciations of diﬀ erent blood 
SFAs with the incidence of type 2 diabetes is scarce.
In this large longitudinal study of the European 
Prospective Investigation into Cancer and Nutrition 
Study (EPIC)-InterAct study,22 we aimed to investigate 
the prospective associations between objectively 
measured individual SFAs in the plasma phospholipid 
fraction and incident type 2 diabetes. We also investi-
gated associations of food consumption with circulating 
SFAs, and studied SFA metabolism indirectly by 
analysing ratios of relevant fatty acids.
Methods
Study design and population
The methods of the InterAct project have previously 
been described in detail.22 To summarise, we did a case-
cohort study that combines the temporal sequence and 
power advantages of a large prospective cohort with the 
measurement eﬃ  ciency of a case-control study. 
Additionally, since the random subcohort is selected 
from the entire cohort independent of the outcome, it 
can be used as a comparison cohort for various outcomes 
of interest. From 340 234 people with 3·99 million 
person-years of follow-up (1991–2007) in eight countries 
of the EPIC study (France, Italy, Spain, UK, Netherlands, 
Germany, Sweden, and Denmark), we veriﬁ ed 
12 403 cases of type 2 diabetes. From the EPIC cohort, 
we also used a random number generator  to randomly 
select 16 835 people with baseline plasma samples in a 
subcohort. After exclusions for prevalent diabetes and 
uncertain diabetes status, 16 154 individuals remained 
in the subcohort, including 778 with incident type 2 
diabetes during follow-up (a feature of the case-cohort 
design).22 From this case cohort of 27 779 participants, 
we excluded 483 for whom no fatty acid data were 
available, leaving 27 296 adults, among whom there were 
12 132 cases of type 2 diabetes and 15 919 subcohort 
participants (including 755 incident cases of type 2 
diabetes within the subcohort; ﬁ gure 1). All participants 
provided written informed consent and the study was 
approved by all local ethics committees.
Procedures
Incident type 2 diabetes was ascertained up until 
Dec 31, 2007, through a review of several sources of 
evidence, reported previously:22 self-report, linkage to 
primary care registers, secondary care registers, 
medication use (drug registers), hospital admissions, 
and mortality data. No diabetes cases were ascertained 
solely by self-report and we sought further evidence for 
all cases with information about incident type 2 diabetes 
from fewer than two independent sources at a minimum, 
including a review of individual medical records in some 
centres. Cases in Denmark and Sweden were identiﬁ ed 
from local and national diabetes and pharmaceutical 
registers and were judged to be veriﬁ ed.
Figure 1: Case-cohort design of the InterAct study and the number of participants included in this analysis
* A random sample of 2055 type 2 diabetes cases from Denmark was included after the exclusion of 2577 cases.
17 928 ascertained cases of type 2 diabetes 16 835 participants in random subcohort
5525 excluded
 2577 in Denmark*
 838 not diabetic
 421 with prevalent diabetes
 101 with diabetes 
   post-censoring
 1588 unknown status
681 excluded
 548 with prevalent diabetes
 4 with diabetes post-censoring
 129 unknown status
16 154 in subcohort
340 234 EPIC participants eligible for 
                  inclusion in EPIC-InterAct
483 excluded because no information
  about circulating fatty acids available
27 296 participants included in current analysis
EPIC-InterAct Study
12 403 verified cases of type 2 diabetes
12 132 verified cases of type 2 diabetes 15 919 in subcohort 
Overlap: 755 verified incident cases of type 2 diabetes in both groups
Overlap: 778  verified incident cases of type 2 
                  diabetes in both groups
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Fatty acids were proﬁ led at the Medical Research Council 
Human Nutrition Research (Cambridge, UK); proﬁ ling 
involved analysis of plasma samples stored at baseline at 
–196°C (or –150°C in Denmark)—a temperature at which 
fatty acids remain stable.6 The assay methods have 
previously been described23 and included hydrolysis and 
methylation to convert phospholipid fatty acids into more 
volatile fatty acid methyl esters and separation of the 
diﬀ erent fatty acids by gas chromatography (J&W HP-88, 
30 m length, 0·25 mm internal diameter [Agilent 
Technologies, CA, USA]) equipped with ﬂ ame ionisation 
detection (7890N GC [Agilent Technologies]). Samples 
from people with type 2 diabetes and subcohort 
participants were processed in random order by centre, 
and laboratory staﬀ  were masked to all participant 
characteristics by the use of anonymised aliquots.
We identiﬁ ed 37 diﬀ erent fatty acids by their retention 
times compared with those of commercial standards 
and expressed each level as percentage of total 
phospholipid fatty acids (mol%). These fatty acids 
included nine SFAs with relative concentrations higher 
than 0·05%: myristic acid (14:0), coeﬃ  cient of variation 
9·4%; pentadecanoic acid (15:0), 11·9%; palmitic acid 
(16:0), 1·6%; heptadecanoic acid (17:0), 4·2%; stearic 
acid (18:0), 2·0%; arachidic acid (20:0), 15·3%; behenic 
acid (22:0), 10·3%; tricosanoic acid (23:0), 18·9%; and 
lignoceric acid (24:0), 14·7%. We used human and 
equine plasma (Sera Laboratories International, West 
Sussex, UK) for quality control.23
Weight and height were measured by trained pro-
fessionals using standardised protocols and were used to 
calculate BMI (in kg/m²). Waist circumference was 
Distribution of fatty acids (mol%) by subcohort category (n=15 919) Distribution of fatty acids (mol%) 
by type 2 diabetes status
Age (years) Sex BMI (kg/m2)* Total 
subcohort
(n=15 919)
Non-cases 
(n=15 164)
Type 2 diabetes 
cases (n=12 132)
<40
(n=1524)
40–<60
(n=10 919)
≥60
(n=3476)
Men
(n=6002)
Women
(n=9917)
<25
(n=7052)
25–<30
(n=6255)
≥30
(n=2502)
All SFAs 45·61
(1·08)
45·94
(1·19)
46·26
(1·25)
46·08
(1·08)
45·91
(1·27)
45·85
(1·22)
46·03
(1·19)
46·21
(1·16)
45·98
(1·21)
45·71
(1·09)
46·13
(1·17)
Myristic acid (14:0) 0·35
(0·11)
0·37
(0·11)
0·39
(0·11)
0·36
(0·10)
0·38
(0·11)
0·38
(0·11)
0·37
(0·11)
0·36
(0·11)
0·37
(0·11)
0·36
(0·11)
0·37
(0·11)
Pentadecanoic acid (15:0) 0·22
(0·06)
0·21
(0·07)
0·22
(0·07)
0·19
(0·07)
0·22
(0·06)
0·23
(0·07)
0·21
(0·07)
0·20
(0·06)
0·21
(0·07)
0·21
(0·06
0·20
(0·06)
Palmitic acid (16:0) 29·88
(1·72)
30·09
(1·69)
30·22
(1·58)
30·32
(1·51)
29·96
(1·75)
30·22
(1·65)
30·09
(1·68)
29·80
(1·67)
30·10
(1·67)
29·93
(1·74)
30·21
(1·67)
Heptadecanoic acid (17:0) 0·42
(0·08)
0·41
(0·09)
0·41
(0·09)
0·39
(0·09)
0·43
(0·09)
0·42
(0·09)
0·41
(0·09)
0·40
(0·10)
0·41
(0·09)
0·41
(0·08)
0·40
(0·09)
Stearic acid (18:0) 13·99
(1·45)
14·11
(1·35)
14·22
(1·24)
14·07
(1·14)
14·15
1·44)
13·83
(1·31)
14·21
(1·29)
14·72
(1·30)
14·12
(1·34)
14·05
(1·47)
14·22
(1·35)
Arachidic acid (20:0) 0·13
(0·04)
0·13
(0·04)
0·14
(0·04)
0·13
(0·04)
0·13
(0·04)
0·13
(0·04)
0·13
(0·04)
0·13
(0·03)
0·13
(0·04)
0·13
(0·04)
0·13
(0·04)
Behenic acid (22:0) 0·23
(0·08)
0·23
(0·07)
0·24
(0·10)
0·23
(0·08)
0·24
(0·08)
0·23
(0·07)
0·24
(0·09)
0·23
(0·06)
0·24
(0·08)
0·23
(0·07)
0·23
(0·07)
Tricosanoic acid (23:0) 0·10
(0·04)
0·11
(0·05)
0·11
(0·06)
0·10
(0·05)
0·11
(0·05)
0·11
(0·05)
0·11
(0·05)
0·11
(0·04)
0·11
(0·05)
0·10
(0·04)
0·10
(0·05)
Lignoceric (24:0) 0·23
(0·06)
0·23
(0·06)
0·23
(0·08)
0·23
(0·07)
0·23
(0·07)
0·23
(0·06)
0·23
(0·07)
0·22
(0·05)
0·23
(0·07)
0·22
(0·06)
0·22
(0·06)
SFA group 1† 44·23
(1·09)
44·57
(1·21)
44·84
(1·26)
44·76
(1·12)
44·50
(1·27)
44·44
(1·22)
44·66
(1·20)
44·88
(1·20)
44·59
(1·22)
44·34
(1·12)
44·80
(1·20)
SFA group 2‡ 0·63
(0·11)
0·62
(0·14)
0·63
(0·14)
0·58
(0·13)
0·65
(0·13)
0·65
(0·13)
0·61
(0·13)
0·60
(0·13)
0·63
(0·13)
0·62
(0·11)
0·60
(0·14)
SFA group 3§ 0·70
(0·19)
0·70
(0·18)
0·72
(0·24)
0·69
(0·20)
0·71
(0·20)
0·71
(0·19)
0·70
(0·22)
0·69
(0·16)
0·70
(0·20)
0·69
(0·18)
0·68
(0·19)
Ratio of 16:1(n-7) to 16:0 0·01
(0·01)
0·02
(0·01)
0·02
(0·01)
0·02
(0·01)
0·02
(0·01)
0·02
(0·01)
0·02
(0·01)
0·02
(0·01)
0·02
(0·01)
0·01
(0·01)
0·02
(0·01)
Ratio of 18:1(n-9) to 18:0 0·70
(0·15)
0·71
(0·16)
0·70
(0·16)
0·72
(0·16)
0·70
(0·16)
0·73
(0·16)
0·70
(0·16)
0·66
(0·16)
0·71
(0·16)
0·70
(0·15)
0·70
(0·16)
Data are mean (SD). The total subcohort of 15 919 people includes 755 people with incident type 2 diabetes as per the design of a case-cohort study. The 15 164 non-cases represent the 
subcohort minus the 755 incident cases of type 2 diabetes in this subcohort; this approach enables a comparison of non-cases with cases of type 2 diabetes. *110 individuals in the subcohort 
had missing BMI values, so BMI data are available for only 15 809 people. †SFA group 1=sum of 14:0, 16:0, and 18:0. ‡SFA group 2=sum of 15:0 and 17:0. §SFA group 3=sum of 20:0, 22:0, 
23:0, and 24:0. SFA=saturated fatty acid.
Table 1: The distribution of plasma phospholipid saturated fatty acids by categories of age, sex, and BMI in the subcohort of the EPIC-InterAct study, and by type 2 diabetes status
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measured by staﬀ , with the exception of French 
participants and a subset of participants from Oxford, 
UK, who self-reported their measurements, and in 
Umeå, Sweden, where this parameter was not recorded. 
We used lifestyle question naires to assess demographics, 
smoking status, medical history, and education level. 
Physical activity was assessed by a validated questionnaire 
from which a four-point ordinal category of activity was 
derived. We assessed habitual diet during the past 
12 months at baseline using country-speciﬁ c validated 
food frequency questionnaires or diet histories. Total 
energy and nutrient intakes were based on the 
standardised EPIC Nutrient Database.24 HbA1C was 
measured in the erythrocyte fraction from samples 
stored at –196°C using the Tosoh-G8 HPLC analyser 
(Tosoh Bioscience, Japan) at Stichting Huisartsen 
Laboratorium (Etten-Leur, Netherlands).
Statistical analysis
We analysed the distribution of individual plasma 
phospholipid fatty acids and expressed them as mol%. 
We estimated country-speciﬁ c hazard ratios (HRs) and 
95% CIs for associations per one standard deviation (SD, 
calculated in the overall subcohort) of each SFA with 
incident type 2 diabetes using Prentice-weighted Cox 
regression,22 which allows for over-representation of 
cases in a case-cohort design, and pooled our ﬁ ndings 
using random-eﬀ ects meta-analysis. Heterogeneity 
between countries was expressed as I² values, and we 
used meta-regression to assess whether the heterogeneity 
was explained by age, BMI, or sex. We adjusted for 
potential confounders as follows: model 1 included age 
(as the underlying timescale), study centre, sex, physical 
activity index, smoking status, and education level. Model 
2 included these parameters plus total energy intake, 
alcohol intake, and BMI. After recording patterns of 
association for the nine individual SFAs, we made a post-
hoc decision to create three additional exposures based 
on groupings of SFAs that ﬁ t with potential biological 
action: group 1 (sum of the even-chain SFAs 14:0, 16:0, 
and 18:0) since these represent both de-novo lipogenesis 
and dietary intake;9,11,14 group 2 (sum of the odd-chain 
SFAs 15:0 and 17:0) as potential sources of dairy fat;7,8 and 
group 3 (sum of the long- or very-long-chain SFAs 20:0, 
22:0, 23:0, and 24:0) since these are under-researched 
SFAs that might undergo distinct peroxisomal fatty acid 
metabolism rather than mitochondrial metabolism.25 In 
an additional analysis, we re-grouped 23:0 into group 2 
because is it also an odd-chain SFA, and removed it from 
group 3. Since stearoyl-CoA desaturase-1 catalyses the 
desaturation of 16:0 to 16:1(n-7) and of 18:0 to 18:1(n-9) 
through the de-novo lipogenesis pathway, we also 
estimated stearoyl-CoA desaturase-1 activity using 
product-to-precursor ratios (ratio of 16:1[n-7] to 16:0 and 
of 18:1[n-9] to 18:0)6,15,26 and assessed each ratio for its 
association with incident type 2 diabetes.
In a sensitivity analysis based on model 2, we analysed 
the eﬀ ects of adjustment for dietary variables (intakes of 
meat, fruit and vegetables, soft drinks, total dairy products, 
and carbohydrates [g/day]). We also did an analysis that 
further accounted for baseline HbA1C value as a covariate. 
To minimise the possibility of reverse causality, we also 
excluded 2348 people with HbA1C of 6·5% or higher at 
baseline or those conﬁ rmed as cases of type 2 diabetes 
Model 1, HR (95% CI) Model 2, HR (95% CI) Model 2a, HR (95% CI) Model 2b, HR (95% CI) Model 2c, HR (95% CI) Model 2d, HR (95% CI)
Myristic acid (14:0) 1·17 (1·11–1·24) 1·15 (1·09–1·22) 1·17 (1·10–1·24) 1·17 (1·11–1·22) 1·13 (1·06–1·21) 1·15 (1·09–1·22)
Pentadecanoic acid (15:0) 0·74 (0·68–0·80) 0·79 (0·73–0·85) 0·79 (0·73–0·86) 0·79 (0·74–0·85) 0·79 (0·74–0·85) 0·80 (0·74–0·86)
Palmitic acid (16:0) 1·22 (1·12–1·33) 1·26 (1·15–1·37) 1·26 (1·15–1·37) 1·19 (1·10–1·28) 1·18 (1·09–1·28) 1·24 (1·13–1·36)
Heptadecanoic acid (17:0) 0·58 (0·54–0·64) 0·67 (0·63–0·71) 0·66 (0·62–0·71) 0·70 (0·67–0·73) 0·70 (0·68–0·73) 0·67 (0·62–0·72)
Stearic acid (18:0) 1·25 (1·17–1·33) 1·06 (1·00–1·13) 1·06 (1·00–1·13) 1·12 (1·08–1·16) 1·12 (1·06–1·18) 1·07 (1·00–1·14)
Arachidic acid (20:0) 0·71 (0·62–0·80) 0·74 (0·65–0·84) 0·74 (0·65–0·84) 0·77 (0·67–0·89) 0·78 (0·68–0·88) 0·76 (0·67–0·86)
Behenic acid (22:0) 0·81 (0·72–0·92) 0·79 (0·69–0·90) 0·79 (0·69–0·90) 0·80 (0·70–0·91) 0·81 (0·71–0·93) 0·80 (0·71–0·91)
Tricosanoic acid (23:0) 0·80 (0·72–0·90) 0·81 (0·72–0·92) 0·81 (0·72–0·92) 0·76 (0·66–0·87) 0·81 (0·72–0·91) 0·83 (0·74–0·93)
Lignoceric acid (24:0) 0·67 (0·57–0·80) 0·72 (0·61–0·85) 0·73 (0·61–0·86) 0·74 (0·63–0·87) 0·75 (0·64–0·88) 0·74 (0·63–0·86)
SFA group 1* 1·55 (1·37–1·76) 1·43 (1·29–1·58) 1·43 (1·29–1·58) 1·39 (1·27–1·52) 1·39 (1·26–1·53) 1·40 (1·27–1·56)
SFA group 2† 0·63 (0·58–0·68) 0·70 (0·66–0·74) 0·69 (0·65–0·74) 0·71 (0·67–0·75) 0·72 (0·69–0·75) 0·70 (0·66–0·75)
SFA group 3‡ 0·68 (0·58–0·81) 0·70 (0·59–0·84) 0·71 (0·59–0·84) 0·70 (0·58–0·85) 0·73 (0·62–0·87) 0·73 (0·62–0·86)
Ratio of 16:1(n-7) to 16:0 1·32 (1·20–1·45) 1·22 (1·13–1·32) 1·22 (1·13–1·32) 1·27 (1·16–1·38) 1·20 (1·12–1·30) 1·22 (1·13–1·32)
Ratio of 18:1(n-9) to 18:0 0·87 (0·81–0·94) 0·99 (0·93–1·05) 0·98 (0·93–1·04) 0·97 (0·91–1·04) 0·96 (0·91–1·03) 0·99 (0·93–1·05)
Data are pooled HRs (95% CI) per 1 SD diﬀ erence in plasma phospholipid SFA (12 132 cases of type 2 diabetes and 15 919 people in the subcohort, including 755 cases of type 2 diabetes in the subcohort). 
HR=hazard ratio. SFA=saturated fatty acid. Model 1: age as the underlying timescale and adjusted for centre, sex, physical activity (inactive, moderately inactive, moderately active, or active), smoking status 
(never, former, or current), and education level (none, primary school completed, technical or professional school, secondary school, or further education). Model 2: adjusted for factors in model 1 plus total 
energy intake (continuous, kcal/day), alcohol intake (yes/no), and BMI (continuous, kg/m2). Models 2a to 2d show the HR for sensitivity analyses: model 2a: model 2 plus intakes of meat, fruit and vegetables, 
soft drinks, and total dairy products (continuous, g/day); model 2b: model 2 plus adjustment for baseline HbA1c value (continuous, mmol/mol); model 2c: model 2, repeated after exclusion of 2348 people with 
HbA1c ≥6·5% (or ≥48 mmol/mol) at baseline; model 2d: model 2, repeated after exclusion of 1048 cases of type 2 diabetes diagnosed within the ﬁ rst 2 years after baseline.*SFA group 1=sum of 14:0, 16:0, and 
18:0. †SFA group 2=sum of 15:0 and 17:0. ‡SFA group 3=sum of 20:0, 22:0, 23:0, and 24:0. 
Table 2: Associations between each plasma phospholipid saturated fatty acid, fatty acid groups, and product-to-precursor ratios and type 2 diabetes
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(n=1048) within the ﬁ rst 2 years after baseline. Further 
sensitivity analyses on model 2 included adjustment for: 
additional potential confounders (dietary carbohydrates 
intake [g/day] and waist circumference [cm]); comorbidity 
(prevalent myocardial infarction, stroke, or cancer); and 
the exclusion of 723 people who were probably dietary 
misreporters (those with a ratio of energy intake to energy 
requirement in the bottom or top 1% of the distribution). 
We also studied the association of SFA quintiles with type 
2 diabetes incidence in models 1 and 2.
We postulated that circulating SFAs would be derived 
from diet and through de-novo lipogenesis, and associated 
with carbohydrate and alcohol con sumption.9,11,12 Within 
the subcohort, we studied associations between each 
circulating SFA and food intakes, using Pearson correlation 
coeﬃ  cients and 95% CI adjusted for age, sex, BMI, and 
energy intake. We used Stata, version 13.1 for all analyses.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
In the subcohort participants (mean age 52·3 years 
[SD 9·2]), SFAs comprised 46% (SD 1·2%) of the total 
phospholipid fatty acids, with the greatest contributors 
being the even-chain fatty acids 16:0 (mean 30·1% 
[SD 1·7%]) and 18:0 (14·1% [1·3%]), whereas 15:0, 17:0, 
and 20:0–24:0 were present in low relative con-
centrations (all <0·5%) (table 1). Older adults, those with 
higher BMI, and men had higher relative concentrations 
of even-chain SFAs (14:0, 16:0, and 18:0), whereas we 
noted the opposite for longer-chain SFAs (20:0, 22:0, 
23:0, and 24:0) (table 1). Relative concentrations of odd-
chain SFAs (15:0 and 17:0) were higher in people with a 
lower BMI and in women, but were similar across 
diﬀ erent age groups (table 1). Appendix p 2 shows SFA 
distribution by country.
Model 2 in table 2 shows that even-chain SFAs were 
each positively associated with type 2 diabetes risk 
individually and when combined (SFA group 1 HR 1·43 
[95% CI 1·29–1·58]). By contrast, odd-chain SFAs were 
each inversely associated with type 2 diabetes indivi-
dually and when combined (SFA group 2 HR 0·70 
[95% CI 0·66–0·74]). Longer-chain SFAs were each 
inversely associated with type 2 diabetes individually 
and when combined (SFA group-3 HR 0·70 [95% CI 
0·59–0·84]). The results were similar when 23:0 was 
included in SFA group 2 and removed from group 3 
(data not shown). Sensitivity analyses showed the same 
results (table 2 and appendix p 3). Analyses with 
quintiles of the fatty acid distributions led to similar 
conclusions in terms of direction and signiﬁ cance of 
associations (appendix p 5). For example, results of 
model 2 showed that the HR (95% CI) for a comparison 
of quintile 5 versus quintile 1 of even-chain SFAs (SFA 
group 1) was 3·66 (2·75– 4·87); for odd-chain SFAs 
(SFA group 2) 0·37 (0·32–0·42); and for longer-chain 
SFAs (SFA group 3) 0·47 (0·35–0·63); in all cases the 
p value for the trend was <0·0001.
Country-speciﬁ c associations were similar overall 
(ﬁ gure 2). Although we recorded evidence of heterogeneity 
(I²=88·1%; p<0·0001), meta-regression analyses showed 
that age, BMI, and sex did not explain this eﬀ ect (data not 
shown).
Among estimated markers of stearoyl-CoA desaturase-1 
activity, the ratio of 16:1(n-7) to 16:0 was signiﬁ cantly 
positively associated with type 2 diabetes, but the ratio of 
18:1(n-9) to 18:0 was not (table 2; appendix pp 3–5).
See Online for appendix
Figure 2: Hazard ratios and 95% CIs for associations between plasma phospholipid saturated fatty acids and 
incident type 2 diabetes
Associations per 1 SD diﬀ erence in (A) even-chain fatty acids (saturated fatty acid [SFA] group 1: the sum of 14:0, 
16:0, and 18:0), (B) odd-chain fatty acids (SFA group 2: the sum of 15:0 and 17:0), and (C) long- and very-long-chain 
fatty acids (SFA group 3: the sum of 20:0, 22:0, 23:0, and 24:0) and type 2 diabetes. Estimates are per country and the 
pooled estimate is based on random-eﬀ ects meta-analysis. The analyses included 12 132 cases of type 2 diabetes and 
15 919 people in the subcohort (including 755 individuals with type 2 diabetes in the subcohort); used age as the 
underlying time variable; and were adjusted for centre, sex, smoking status, alcohol intake, physical activity, 
education level, total energy intake, and BMI. 
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All three groups of SFAs were modestly or weakly 
correlated with foods, but with overall distinct patterns 
across fatty acid groups (ﬁ gure 3). Even-chain SFAs were 
positively associated with alcohol, soft drinks, margarine, 
and potatoes, and negatively associated with fruit and 
vegetables, and both olive oil and vegetable oil (ﬁ gure 3A). 
By contrast, odd-chain SFAs generally showed positive 
associations with dairy products, cakes and cookies, nuts 
and seeds, and fruit and vegetables, but negative 
associations with red and processed meat, soft drinks, 
alcohol, and margarine (ﬁ gure 3B). The overall correlations 
for longer-chain SFAs were similar to, but weaker than, 
those for odd-chain SFAs (ﬁ gure 3C).
Discussion
In this large prospective case-cohort study, we investigated 
the association of nine individual SFAs with the risk of type 
2 diabetes, and recorded distinct patterns of association. 
Even-chain SFAs (14:0, 16:0, and 18:0) were positively 
associated with the incidence of type 2 diabetes, whereas 
odd-chain SFAs (15:0 and 17:0) and longer-chain SFAs 
(20:0, 22:0, 23:0, and 24:0) were inversely associated with 
type 2 diabetes. Our ﬁ ndings of the diﬀ erential associations 
of individual circulating SFAs with the risk of type 2 
diabetes are in line with the recent debate about the adverse 
eﬀ ects of SFAs.2,27 Our results indicate that diﬀ erent SFAs 
have diﬀ erential associations with metabolic risk. 
Therefore, to classify all SFAs as having adverse health 
eﬀ ects, as has conventionally been done, does not 
acknowledge their potentially heterogeneous associations.
The existing evidence around this topic is inconclusive 
and is based on only a few studies with small sample 
size, in which the number of participants with type 2 
diabetes ranged from 34 in a Finnish study21 to 673 in a 
German study.15 Null associations have been recorded 
for the even-chain SFAs 14:0, 16:0, and 18:0,17-21 although 
positive associations have also been reported for 16:0 
and 18:0.15,16,19 Some studies reported an inverse 
association between type 2 diabetes risk and odd-chain 
SFAs 15:017,18 and 17:0,16,17 whereas one showed an inverse 
association only for the sum of 15:0 and 17:0,15 and one a 
non-signiﬁ cant association with 15:0.20 Only one study15 
reported a signiﬁ cant association with longer-chain 
SFAs, but showed a positive association for 24:0 (unlike 
the inverse association recorded in our study). Our 
ﬁ ndings with 12 132 cases of type 2 diabetes therefore 
provide the strongest evidence so far for diﬀ erential 
associations between nine individual SFAs and type 2 
diabetes (panel).
Our pattern of ﬁ ndings for the correlations of SFA with 
food intakes are consistent with previous evidence from 
feeding intervention studies showing that even-chain 
SFAs (14:0, 16:0, and 18:0) are derived from de-novo 
lipogenesis, through which carbohydrates and alcohol are 
converted to fatty acids in the liver or adipose tissue.6,9,11,12 
Our ﬁ nding of a positive association of type 2 diabetes 
with the product-to-precursor ratio of 16:1(n-7) to 16:0 but 
not with the 18:1(n-9) to 18:0 ratio (as markers of de-novo 
lipogenesis) is also consistent with previous observations 
in smaller samples.15,17 However, studies with isotope-
Figure 3: Adjusted Pearson correlation coeﬃ  cients for the correlation between plasma phospholipid saturated fatty acids (mol%) and types of self-reported food intake (g/day) in the 
subcohort (n=15 919)
Correlations for (A) even-chain fatty acids (saturated fatty acid [SFA] group 1: the sum of 14:0, 16:0 and 18:0), (B) odd-chain fatty acids (SFA group 2: the sum of 15:0 and 17:0), and (C) long- and 
very-long-chain fatty acids (SFA group 3: the sum of 20:0, 22:0, 23:0 and 24:0). Correlations are adjusted for age, sex, BMI, and total energy intake. Error bars are 95% CIs.
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labelled dietary fatty acids show that some incorporation 
of these SFAs into phospholipids occurs,13 and evidence 
also indicates that de-novo lipogenesis is reduced when 
dietary starch is substituted for sugar, which suggests the 
importance of carbohydrate type.11 The extent to which de-
novo lipogenesis might also contribute to the circulating 
levels of these SFAs could be quite low under conditions 
of relatively high-fat habitual diets in free-living Western 
populations.14 Because existing knowledge is insuﬃ  cient, 
future research is needed to quantify the eﬀ ects of 
habitual diets and metabolic state on blood concentrations 
of SFAs. Importantly, measurements of even-chain SFAs 
in the blood should not be used to directly interpret 
dietary SFAs.
Given that de-novo lipogenesis is the underlying 
process for increased levels of even-chain SFAs, this 
pathway might increase the risk of type 2 diabetes 
through hepatic steatosis and related mechanisms.28 
Direct eﬀ ects of even-chain SFAs could also promote the 
development of type 2 diabetes: biochemical studies 
indicate toxic eﬀ ects speciﬁ cally of 16:0, including 
activation of inﬂ ammatory cytokines and lipotoxicity to 
pancreatic β cells.29 Epidemiological research cannot 
address biological mechanisms and should therefore be 
complemented by experimental studies.
Our ﬁ nding of positive correlations of dairy products 
with odd-chain SFAs (15:0 and 17:0) is consistent with 
previous evidence that these SFAs are markers of 
exogenous origin dairy fat intake.6–8 Although residual 
confounding by other dairy components such as 
vitamin D or calcium cannot be ruled out, and nor can 
the possible eﬀ ects of processes related to fermentation 
of dairy products,4,5,30 our strong ﬁ ndings for odd-chain 
SFAs in the blood lend support to accumulating evidence 
of an inverse association between dairy products and 
type 2 diabetes risk.4,5
Our report of an inverse association between the very-
long-chain SFAs and type 2 diabetes provides the largest 
appraisal so far of an as-yet under-researched group of 
SFAs that might undergo distinct fatty acid metabolism 
through peroxisomal fatty acid oxidation.25 To our 
knowledge, the sources and metabolic eﬀ ects of very-
long-chain SFAs are largely unknown, and our new 
ﬁ ndings should provide the impetus for further research 
into this group of fatty acids.
The main limitation of our study was that SFAs were 
measured at one timepoint only, and intra-individual 
variation over time is likely. However, we would not expect 
any errors to be diﬀ erential with respect to case status. We 
could only assess relative—not absolute—concentrations 
of fatty acids (in mol%), but this valid approach is often 
used in epidemiological research and tends to provide a 
better interpretation of metabolic inter-relationships than 
do absolute measurements.6 Fatty acids were measured in 
long-term stored samples, but stability is likely given that 
samples were stored at –196°C.6 Plasma phospholipid 
SFAs might be indicative of both dietary and metabolic 
inﬂ uences, aﬀ ected by interplay of complex exogenous and 
genetic factors, which we were unable to tease out. This 
raises caution against inferring dietary consumption on 
the basis of measurements of SFAs that are not exclusively 
exogenously derived. Our indirect estimation of fatty acid 
desaturation ratios has limited use as a biomarker of 
stearoyl-CoA desaturase-1 activity,26 but direct measures 
involving liver biopsies or tracer techniques are not feasible 
in epidemiological studies. Our outcome ascertainment 
was complete for the entire cohort and therefore does not 
have the problem of ascertainment bias consequent on a 
requirement for attendance at a follow-up visit, but was 
limited by a reliance on clinically incident diabetes. 
However, we minimised false positives by applying 
rigorous veriﬁ cation criteria to ensure that no case was 
included unless veriﬁ ed by at least two independent 
sources. Although false negatives were also possible 
because of undiagnosed incident diabetes, such 
Panel: Research in context
Systematic review
We searched PubMed for relevant articles using terms 
related to the exposure (“saturated fatty acids” or “saturated 
fat” or “myristic” or “palmitic” or “stearic” or “myristate” or 
“palmitate” or “stearate” or “dairy” or “ruminant” or 
“odd-numbered” or “odd numbered” or “odd chain” or 
“odd-chain” or “long chain” or “long-chain”), the outcome 
(“diabetes”), and the prospective study design (“cohort” or 
“nested”). We reviewed articles resulting from these 
searches, relevant references cited in those articles, and our 
own reference databases. Our search showed that past 
evidence was inconclusive, based on prospective studies 
with small sample size in which the number of type 2 
diabetes events ranged from 34 to 673, and only a small 
number of individual saturated fatty acids were studied.
Interpretation
In the largest study so far, including 12 132 cases of incident 
type 2 diabetes across eight European countries in whom we 
measured a set of nine individual plasma phospholipid 
saturated fatty acids (SFAs), we showed that diﬀ erent 
individual SFAs were independently associated with incident 
type 2 diabetes in opposite directions. The inverse associations 
between diabetes and odd-chain SFAs (15:0 and 17:0)—that 
are mainly exogenously derived—can be interpreted in terms 
of dietary dairy fat intake, but the interpretation of positive 
associations with even-chain SFAs—such as 16:0 and 18:0—is 
more complex. More research is needed to clarify the extent to 
which the positive associations between these even-chain 
SFAs and diabetes reﬂ ect complex interplay between intakes 
of dietary fat, carbohydrates, and alcohol and endogenous 
de-novo lipogenesis that induces synthesis of even-chain SFAs. 
Our ﬁ ndings provide strong biological evidence that individual 
SFAs are not homogenous in their eﬀ ects, and lend support to 
the importance of recognising diﬀ erences between the 
diﬀ erential health eﬀ ects of subtypes of blood SFAs.
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misclassiﬁ cation can be assumed to be non-diﬀ erential 
with regard to the exposure and therefore any potential 
bias would be unlikely to change our conclusions based on 
a relative scale (HR) in our analysis. We also minimised 
the potential for reverse causation bias from undiagnosed 
prevalent diabetes by applying three separate sensitivity 
analyses to test the robustness of our results: adjustment 
for baseline HbA1C, exclusion of those with raised HbA1C 
at baseline, and exclusion of those with diabetes diagnosed 
within 2 years of baseline.
The strengths of our study include the large sample 
size, prospective study design and hence the ability to 
study the temporality of association with type 2 diabetes, 
long follow-up, the inclusion of populations from eight 
European countries with diverse dietary intakes, 
comprehensive type 2 diabetes case ascertainment and 
veriﬁ cation, adjustment for many potential confounders, 
and a series of sensitivity analyses. We were able to 
analyse the associations of type 2 diabetes with a large 
number of objectively measured SFAs.
In conclusion, our ﬁ ndings indicate that diﬀ erent 
individual plasma phospholipid SFAs are diﬀ erentially 
associated with risk of type 2 diabetes, which supports 
the importance of recognising that individual blood SFAs 
exert heterogeneous eﬀ ects. Further research into an 
increased understanding of dietary versus endogenous 
metabolic sources of circulating individual SFAs will 
help to inform updated public health messages about the 
dietary intake of saturated fats and their sources.
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